Nervgen Pharma Corp (TSE:NGEN) has released an update.
NervGen Pharma Corp. is set to showcase two posters at the American Spinal Injury Association’s 51st Annual Scientific Meeting, highlighting advances in spinal cord injury (SCI) treatment. The presentations will discuss the use of motor evoked potentials (MEPs) as a biomarker in SCI recovery trials and provide an update on the ongoing Phase 1b/2a clinical trial for their drug NVG-291. The trial aims to demonstrate NVG-291’s potential in repairing nervous system damage in both chronic and subacute SCI patients.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
